Ertapenem

Revision as of 02:22, 9 August 2012 by WikiBot (talk | contribs) (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +))
Jump to navigation Jump to search
Ertapenem
Error creating thumbnail: File missing
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H25N3O7S
Molar mass475.516 g/mol

WikiDoc Resources for Ertapenem

Articles

Most recent articles on Ertapenem

Most cited articles on Ertapenem

Review articles on Ertapenem

Articles on Ertapenem in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ertapenem

Images of Ertapenem

Photos of Ertapenem

Podcasts & MP3s on Ertapenem

Videos on Ertapenem

Evidence Based Medicine

Cochrane Collaboration on Ertapenem

Bandolier on Ertapenem

TRIP on Ertapenem

Clinical Trials

Ongoing Trials on Ertapenem at Clinical Trials.gov

Trial results on Ertapenem

Clinical Trials on Ertapenem at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ertapenem

NICE Guidance on Ertapenem

NHS PRODIGY Guidance

FDA on Ertapenem

CDC on Ertapenem

Books

Books on Ertapenem

News

Ertapenem in the news

Be alerted to news on Ertapenem

News trends on Ertapenem

Commentary

Blogs on Ertapenem

Definitions

Definitions of Ertapenem

Patient Resources / Community

Patient resources on Ertapenem

Discussion groups on Ertapenem

Patient Handouts on Ertapenem

Directions to Hospitals Treating Ertapenem

Risk calculators and risk factors for Ertapenem

Healthcare Provider Resources

Symptoms of Ertapenem

Causes & Risk Factors for Ertapenem

Diagnostic studies for Ertapenem

Treatment of Ertapenem

Continuing Medical Education (CME)

CME Programs on Ertapenem

International

Ertapenem en Espanol

Ertapenem en Francais

Business

Ertapenem in the Marketplace

Patents on Ertapenem

Experimental / Informatics

List of terms related to Ertapenem


Overview

Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz®. It is structurally very similar to meropenem in that it possess a 1-β-methyl group.

Indications

Ertapenem has been designed to be effective against Gram negative bacteria. It is not active against MRSA, ampicillin-resistant enterococci, Pseudomonas aeruginosa or Acinetobacter species. Ertapenem also has clinically useful activity against anaerobic bacteria.

Ertapenem is marketed by Merck as a first-line treatment for community-acquired infections. It should not be used as empirical treatment for hospital-acquired infections because of its lack of activity against Pseudomonas aeruginosa. In practice, it is reserved primarily for use against ESBL-producing and high level AmpC-producing Gram-negative bacteria.

Dosage

Ertapenem is dosed as 1g given by intravenous injection over 30 minutes, or 1g diluted with 3.2ml of 1% lidocaine given intramuscularly. There is no oral preparation of ertapenem available. Ertapenem cannot be mixed with glucose.

The marketing slogan for ertapenem is "The Power of One", because the dose is one gram, once a day.

Pharmacology

Unlike imipenem and meropenem, ertapenem is highly protein bound, which explains its long half life (4 hours).

Ertapenem is excreted primarily (80%) by the kidneys. Metabolism by the liver is not clinically important and does not affect dosing.

Patients on haemodialysis should be given ertapenem at least 6 hours before dialysis. If it is given less than six hours before dialysis, then the patient should be given an additional dose of 150mg IV after dialysis. Ideally, patients on haemodialysis should be given ertapenem immediately following dialysis.

Resistance

Acquired resistance to ertapenem is usually mediated by up-regulation of efflux mechanisms and by the selection of porin-deficient mutants. Organisms that produce a metallo-β-lactamase are innately immune to ertapenem (as well as all carbapenems) (Reference needed).

Side effects

There are few adverse effects of ertapenem. The only absolute contra-indication is a previous anaphylactic reaction to ertapenem or other β-lactam antibiotic. There are no studies done in pregnant women, so the manufacturers cannot comment on its safety in pregnancy. In 2006, Ertapenem is now approved for pediatric use in certain infections. Ertapenem is not recommended for children under 3 months of age and children with meningitis.

Use of all antibiotics is associated with increased rates of resistance (although carbapenem resistance is currently rare). There is particular worry that although ertapenem has no clinically useful activity against Pseudomonas aeruginosa, widespread use of ertapenem could still lead to increased carbapenem resistance in Pseudomonas (Livermore et al. 2005).

Like many antibiotics, Clostridium difficile colitis has been associated with its use.

References

  • Livermore DM, Mushtaq S, Warner M (2005). "Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems". J Antimicrob Chemother. 55 (3): 306&ndash, 311.

Template:WH Template:WS